Mycenax Biotech Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 225.55 million compared to TWD 292.22 million a year ago. Net income was TWD 18.31 million compared to TWD 114.39 million a year ago. Basic earnings per share from continuing operations was TWD 0.12 compared to TWD 0.85 a year ago. Diluted earnings per share from continuing operations was TWD 0.12 compared to TWD 0.85 a year ago.